Sort

Search

01/11/2024 Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
Krebs, MG, Forster, M, Majem, M, Peguero, J, Iams, W, Clay, T, Roxburgh, P, Doger, B, Bajaj, P, Barba, A, Perera, S, Mueller, C, Triebel, F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11)DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:(Q/D).
01/11/2024 Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Provencio, M, Nadal, E, Insa, A, Campelo, RG, Casal, J, Dómine, M, Massuti, B, Majem, M, Rodríguez-Abreu, D, Martínez-Marti, A, de Castro, J, de Antonio, DG, Macia, I, Figueroa, S, Vago, LF, Calvo, V, Palmero, R, Sierra-Rodero, B, Martínez-Toledo, C, Molina-Alejandre, M, Serna-Blasco, R, Romero, A, Cruz-Bermúdez, A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2024; 25(11)DOI:10.1016/S1470-2045(24)00498-4. PMID:39419061. IF:35.900(Q1/1D).
01/11/2024 Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection
Borque-Fernando, A, Zapatero, A, Manneh, R, Alonso-Gordoa, T, Couñago, F, Domínguez-Esteban, M, López-Valcárcel, M, Rodríguez-Antolín, A, Sala-González, N, Sanmamed, N, Maroto, P. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection. Actas Urologicas Espanolas. 2024; 48(9)DOI:10.1016/j.acuro.2024.03.002. PMID:38740263. IF:1.200(Q3/7D).
01/11/2024 Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
Gray, JE, Markovets, A, Reungwetwattana, T, Majem, M, Nogami, N, Peled, N, Lee, JS, Cho, BC, Chewaskulyong, B, John, T, Han, JY, Sebastian, M, Todd, A, Rukazenkov, Y, Barrett, C, Chmielecki, J, Lee, SM, Ramalingam, SS, Hartmaier, R. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 2024; 19(11)DOI:10.1016/j.jtho.2024.07.008. PMID:39029876. IF:20.800(Q1/1D).
01/11/2024 Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study
Mirallas, O, Martin-Cullell, B, Navarro, V, Vega, KS, Recuero-Borau, J, Gómez-Puerto, D, López-Valbuena, D, de Torres, CS, Andurell, L, Pedrola, A, Berché, R, Palmas, F, Ucha, JM, Villacampa, G, Rezqallah, A, Sanz-Beltran, J, Bach, R, Bueno, S, Viaplana, C, Molina, G, Hernando-Calvo, A, Aguilar-Company, J, Roca, M, Muñoz-Couselo, E, Martínez-Martí, A, Alonso, A, Eremiev, S, Macarulla, T, Oaknin, A, Saura, C, Élez, E, Felip, E, Peñuelas, A, Burgos, R, Pardo, PG, Garralda, E, Tabernero, J, Serradell, S, Servitja, S, Paez, D, Dienstmann, R, Carles, J. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study. Lancet Regional Health-Europe. 2024; 46DOI:10.1016/j.lanepe.2024.101063. PMID:39529819. IF:13.000(Q1/1D).
01/11/2024 The current situation of tutoring in specialised training in otorhinolaryngology-head and neck surgery in Spain. Where are we? Where do we want to go?
Canduela, PDD, Jurado, FXA, Beltrán, JD, Ruiz, CM, Gadea, AS, López, F. The current situation of tutoring in specialised training in otorhinolaryngology-head and neck surgery in Spain. Where are we? Where do we want to go?. Acta Otorrinolaringologica Espanola. 2024; 75(6)DOI:10.1016/j.otorri.2024.03.002. PMID:. IF:(Q/D).
01/11/2024 Evaluating the effect of passive cooling strategies in school buildings on children's well-being in Barcelona: A quasi-experimental, mixed methods study
Sanz-Mas, M, Continente, X, Brugueras, S, Marí-Dell'Olmo, M, Oliveras, L, López, MJ. Evaluating the effect of passive cooling strategies in school buildings on children's well-being in Barcelona: A quasi-experimental, mixed methods study. The Science of the total environment. 2024; 949DOI:10.1016/j.scitotenv.2024.175104. PMID:39079644. IF:8.000(Q1/2D).
01/11/2024 Elective splenectomy for hematological diseases: a vanishing indication
Fernández-Ananin, S, Novelli, S, Cabré, LC, Riera, CV, Vàzquez, EB, Verdaguer, EJ, Targarona, EM. Elective splenectomy for hematological diseases: a vanishing indication. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES. 2024; 38(11)DOI:10.1007/s00464-024-11071-8. PMID:39210059. IF:2.700(Q1/3D).
01/11/2024 Effectiveness of official food safety control in Barcelona city: Digital and traditional inspections
Grau-Noguer, E, Rodríguez-Sanz, M, Suppi, R, Serratosa, J, Lundén, J, Bolao, A, Cedano, D, Portaña, S. Effectiveness of official food safety control in Barcelona city: Digital and traditional inspections. FOOD CONTROL. 2024; 165DOI:10.1016/j.foodcont.2024.110655. PMID:. IF:6.300(Q1/2D).
01/11/2024 Strategies for the prevention and non-pharmacological treatment of obesity. Models of care
Rosales, A, Mendoza, L, Minambres, I. Strategies for the prevention and non-pharmacological treatment of obesity. Models of care. Atencion Primaria. 2024; 56(11)DOI:10.1016/j.aprim.2024.102978. PMID:38820670. IF:1.600(Q2/4D).
01/11/2024 Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
Paternostro, R, Kwanten, WJ, Hofer, BS, Semmler, G, Bagdadi, A, Luzko, I, Hernández-Gea, V, Graupera, I, García-Pagán, JC, Saltini, D, Indulti, F, Schepis, F, Moga, L, Rautou, PE, Llop, E, Téllez, L, Albillos, A, Fortea, JI, Puente, A, Tosetti, G, Primignani, M, Zipprich, A, Vuille-Lessard, E, Berzigotti, A, Taru, MG, Taru, V, Procopet, B, Jansen, C, Praktiknjo, M, Gu, WY, Trebicka, J, Ibanez-Samaniego, L, Bañares, R, Rivera-Esteban, J, Pericas, JM, Genesca, J, Alvarado, E, Villanueva, C, Larrue, H, Bureau, C, Laleman, W, Ardevol, A, Masnou, H, Vanwolleghem, T, Trauner, M, Mandorfer, M, Francque, S, Reiberger, T. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD. JOURNAL OF HEPATOLOGY. 2024; 81(5)DOI:10.1016/j.jhep.2024.05.033. PMID:38823501. IF:33.000(Q1/1D).
01/11/2024 Transcatheter Aortic Valve Replacement: Latest Advances and Prospects
Asmarats, L, Arzamendi, D. Transcatheter Aortic Valve Replacement: Latest Advances and Prospects. Journal of Clinical Medicine. 2024; 13(21)DOI:10.3390/jcm13216583. PMID:39518721. IF:2.900(Q1/2D).
01/11/2024 SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).
Soria Rivas A, Escobar Álvarez Y, Blasco Cordellat A, Majem Tarruella M, Molina Mata K, Motilla de la Cámara M, Del Mar Muñoz Sánchez M, Zafra Poves M, Beato Zambrano C, Cabezón Gutierrez L. SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).. Clinical & Translational Oncology. 2024; 26(11)DOI:10.1007/s12094-024-03502-8. PMID:38822976. IF:(Q/D).
30/10/2024 Dupilumab treatment in paediatric atopic dermatitis (2-18 years): Spanish multicentre retrospective real-world study
Iznardo, H, Roé, E, Vicente, A, Prat, C, Casals, M, Martín-Santiago, A, Esteve, A, Viñas, M, Munera-Campos, M, Corella, F, Mollet, J, Figueras-Nart, I, Vila, A, Soria, X, Azón-Masoliver, A, Marqués-Martín, L, Nadal-Lladó, C, Bel, S, Pujol-Montcusí, J, Bertolín-Colilla, M, Curto-Barredo, L, Melé-Ninot, G, Evole, M, Berbegal, L, Puig, L, Baselga, E. Dupilumab treatment in paediatric atopic dermatitis (2-18 years): Spanish multicentre retrospective real-world study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2024; 50(1)DOI:10.1093/ced/llae300. PMID:39093288. IF:2.800(Q2/4D).
29/10/2024 BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice
Villanueva, V, Villar, EG, Fernandez-Cabrera, A, Zurita, J, Lopez-Gonzalez, FJ, Rodríguez-Osorio, X, Parejo-Carbonell, B, Estevez, JC, Mercedes-Alvarez, B, Ojeda, J, Rubio-Roy, M, Garcia-Escrivá, A, Gómez-Ibáñez, A, Martinez-Poles, J, Martinez-Agredano, P, Calle, R, Sierra-Marcos, A, Gonzalez, AM, Herrera, JD, Rodriguez-Uranga, J, Cabezas, B, Martinez, E, Renau, J, de Toledo, M, Hampel, KG, Alarcón, C, Barceló, MI, Monterde, A, Lara, LB, Sansa, G, Serratosa, JM. BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice. Epilepsia Open. 2024; 9(6)DOI:10.1002/epi4.13078. PMID:39470722. IF:2.900(Q2/4D).
29/10/2024 Incidence, Predictors, and Clinical Impact of Early Safety After Transcatheter Aortic Valve Replacement According to VARC-3 Criteria
Avvedimento, M, Gonzálvez-García, A, Cepas-Guillen, PL, Ternacle, J, Urena, M, Alperi, A, Fernández, GV, Franco, LN, Vilalta, V, Esposito, G, Campelo-Parada, F, Indolfi, C, Del Trigo, M, Munoz-Garcia, A, Melon, NMM, Asmarats, L, Regueiro, A, del Val, D, Auffret, V, Beaumont, E, Rodes-Cabau, J. Incidence, Predictors, and Clinical Impact of Early Safety After Transcatheter Aortic Valve Replacement According to VARC-3 Criteria. JACC-JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024; 84(18)DOI:. PMID:. IF:22.300(Q1/1D).
29/10/2024 Validation of the Valve Academic Research Consortium High Bleeding Risk Definition in Patients Undergoing Transcatheter Aortic Valve Replacement
Avvedimento, M, Cepas, P, Ternacle, J, Urena, M, Alperi, A, Fernandez, GV, Franco, LN, Vilalta, V, Esposito, G, Campelo-Parada, F, Indolfi, C, Del Trigo, M, Munoz-Garcia, A, Melon, NMM, Asmarats, L, Regueiro, A, del Val, D, Auffret, V, Cote, M, Mehran, R, Capodanno, D, Garot, P, Rodes-Cabau, J. Validation of the Valve Academic Research Consortium High Bleeding Risk Definition in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC-JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024; 84(18)DOI:. PMID:. IF:22.300(Q1/1D).
29/10/2024 Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.
Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, Martin Lopez AA, Iraola-Truchuelo J, Delgado J, Perez A, Guerreiro M, Caballero AC, Martinez-Cibrian N, Luzardo Henriquez H, Sanchez Pina JM, Sancho JM, Ghesquieres H, Mussetti A, Lopez Corral L, Hernani R, Reguera JL, Sureda A, Bosch F, Martin Garcia-Sancho A, Kwon M, Subklewe M, Kuhnl A, Bachy E, Barba P, Villacampa G, Abrisqueta P. Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.. Journal of Hematology & Oncology. 2024; 17(1)DOI:10.1186/s13045-024-01608-8. PMID:39468591. IF:(Q/D).
28/10/2024 Hereditary transthyretin amyloidosis caused by Val142Ile variant in Spain: phenotypic characteristics, geographic distribution and population frequency
Seminario, FD, Aventin, BP, Eiros, R, Freire, JL, Sevilla, T, Carbayo, A, Llongueras, P, Garcia-Alvarez, A, Ripoll-Vera, T, Macias, R, Vilches, S, Ruiz-Bustillo, S, Achaga, XA, Ordas, JG, Gonzalez-Costello, J. Hereditary transthyretin amyloidosis caused by Val142Ile variant in Spain: phenotypic characteristics, geographic distribution and population frequency. EUROPEAN HEART JOURNAL. 2024; 45DOI:10.1093/eurheartj/ehae666.2073. PMID:. IF:35.600(Q1/1D).
28/10/2024 Effects of exercise referral schemes enhanced with behavioural self-management strategies on functional capacity and self-reported disability in community-dwelling older adults. Secondary results from the SITLESS multi-country, three-armed randomized controlled trial
Olsen, PO, Tully, MA, Cruz, BD, Giné-Garriga, M, Coll-Planas, L, Roqué, M, Rothenbacher, D, Dallmeier, D, Sansano-Nadal, O, Blackburn, NE, Wilson, JJ, Skjodt, M, Caserotti, P. Effects of exercise referral schemes enhanced with behavioural self-management strategies on functional capacity and self-reported disability in community-dwelling older adults. Secondary results from the SITLESS multi-country, three-armed randomized controlled trial. AGE AND AGEING. 2024; 53(10)DOI:10.1093/ageing/afae225. PMID:39468725. IF:7.100(Q1/1D).